Prävention der Virushepatitis B und C bei chronischer Niereninsuffizienz

Zusammenfassung

Dialysepatienten und das -personal sind besonders gefährdet, sich mit einer Virushepatitis zu infizieren. Die Wirksamkeit der Hepatitis-B-Impfung ist bei fortgeschrittener chronischer Niereninsuffizienz vermindert. Dies erschwert die Aufrechterhaltung einer Herdenimmunität und erfordert teilweise Impf- und Monitoringstrategien, die von denen in der Allgemeinbevölkerung abweichen. Die rationale Abwägung von Kosten und Nutzen gehören zur Impfentscheidung dazu.

Publication History

Article published online:
11 February 2025

• Literatur

• 1 Maupas P, Goudeau A, Coursaget P. et al. Immunisation against hepatitis B in man. Lancet 1976; 1: 1367-1370
• 2 World Health Organization: Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Geneva: World Health Organization; 2024. Im Internet: Accessed November 03, 2024 at: https://www.who.int/publications/i/item/9789240091672
• 3 Dudareva S, Faber M, Zimmermann R. et al. Epidemiologie der Virushepatitiden A bis E in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung. Gesundheitsschutz 2022; 65: 149-158
• 4 Poethko-Müller C, Zimmermann R, Hamouda O. et al. Die Seroepidemiologie der Hepatitis A, B und C in Deutschland. Bundesgesundheitsblatt 2013; 56: 707-715
• 5 Steffen G, Sperle I, Harder T. et al. Hepatitis B vaccination coverage in Germany: systematic review. BMC. Infect Dis 2021; 21: 817
• 6 Kaboth U, Schober A, Klinge O. et al. Endemie Australia-Antigen positiver Hepatitiden in einem Dialysezentrum. Dtsch Med Wochenschr 1971; 96: 1235-1241
• 7 Nguyen DB, Gutowski J, Ghiselli M. et al. A Large Outbreak of Hepatitis C Virus Infections in a Hemodialysis Clinic. Infect Control Hosp Epidemiol 2016; 37: 125-133
• 8 Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs 2015; 38: 471-480
• 9 Khalesi Z, Razizadeh MH, Javadi M. et al. Global epidemiology of HBV infection among hemodialysis patients: A systematic review and meta-analysis. Microb Pathog 2023; 179: 106080
• 10 Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006–2007. QuaSi-Niere. 2008 Im Internet: Accessed November 03, 2024 at: https://www.bundesverband-niere.de/wp-content/uploads/2019/02/QuaSi-Niere-Bericht_2006–2007.pdf
• 11 Pittet D, Hugonnet S, Harbarth S. et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356: 1307-1312
• 12 Girndt M, Backus G, Beige J. et al. Deutsche Gesellschaft für Nephrologie, Hrsg. Leitlinie zu Infektionsprävention und Hygiene 2019 als Ergänzung zum Dialysestandard. 2020 Im Internet: Accessed November 03, 2024 at: https://www.dgfn.eu/dialyse-standard.html
• 13 Schmitt A, Sarrazin C. Hepatitis C: von der Diagnose zur weltweiten Virus-Elimination. Dtsch Med Wochenschr 2024; 149: 955-961
• 14 London WT, DiFiglia M, Sutnick AI. et al. An epidemic of hepatitis in a chronic hemodialysis unit. NEJM 1969; 281: 571-578
• 15 Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol 2016; 65: 835-848
• 16 Hilleman MR, Buynak EB, Roehm RR. et al. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 1975; 270: 401-404
• 17 Vesikari T, Finn A, van Damme P. et al. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial. JAMA Netw Open 2021; 4: e2128652
• 18 Jackson S, Lentino J, Kopp J. et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 2018; 36: 668-674
• 19 Champion CR. Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant. Ann Pharmacother 2021; 55: 783-791
• 20 Jilg W, Lorbeer B, Schmidt M. et al. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984; 2: 1174-1175
• 21 van Damme P, Dionne M, Leroux-Roels G. et al. Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. J. Viral Hepat 2019; 26: 1066-1075
• 22 Robert-Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2024. Epidemiol Bull. 2024: 1-72
• 23 Ständige Impfkommission am Robert Koch-Institut: Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen Hepatitis B. Epidemiol Bull. 2013: 371-381
• 24 Pol S, Legendre C, Mattlinger B. et al. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990; 11: 385-387
• 25 Köhler H, Arnold WC, Renschin G. et al. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124-128
• 26 Schroth RJ, Hitchon CA, Uhanova J. et al. Hepatitis B vaccination for patients with chronic renal failure. Cochrane. Database Syst Rev 2004; CD003775
• 27 Barraclough KA, Wiggins KJ, Hawley CM. et al. Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination. Am J Kidney Dis 2009; 54: 95
• 28 Yousaf F, Gandham S, Galler M. et al. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. Ren Fail 2015; 37: 1080-1088
• 29 Tong NK, Beran J, Kee SA. et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303
• 30 Janssen RS, Mangoo-Karim R, Pergola PE. et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 2013; 31: 5306-5313
• 31 Girndt M, Plüer M, Dellanna F. et al. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study. Hum Vaccin Immunother 2022; 2136912
• 32 Dalrymple LS, Katz R, Kestenbaum B. et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59: 356-363
• 33 Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. Am J Kidney Dis 2020; 75: 417-425
• 34 Babel N, Hugo C, Westhoff TH. Vaccination in patients with kidney failure: lessons from COVID-19. Nat Rev Nephrol 2022; 18: 708-723
• 35 Girndt M, Köhler H, Schiedhelm-Weick E. et al. T-cell activation defect in hemodialysis patients: Evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359-365
• 36 Girndt M, Sester M, Sester U. et al. Defective expression of B7–2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001; 59: 1382-1389
• 37 Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 2018; 33: iii35-iii40
• 38 Kudo S, Goto H. Intrarenal handling of recombinant human interleukin-1alpha in rats: mechanism for proximal tubular protein reabsorption. J Interferon Cytokine Res 1999; 19: 1161-1168
• 39 Zhang D, Jiang SL, Rzewnicki D. et al. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 1995; 310: 143-148
• 40 Sester U, Sester M, Hauk M. et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1217-1223
• 41 Girndt M, Sester U, Sester M. et al. The interleukin-10 promotor genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60: 2385-2391
• 42 Girndt M, Fiedler R, Martus P. et al. High cut-off dialysis in chronic hemodialysis patients. Eur. J Clin Invest 2015; 45: 1333-1340
• 43 Zickler D, Schindler R, Willy K. et al. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One 2017; 12: e0169024
• 44 Trojanowicz B, Ulrich C, Fiedler R. et al. Impact of serum and dialysates obtained from chronic hemodialysis patients maintained on high cut-off membranes on inflammation profile in human THP-1 monocytes. Hemodial Int 2017; 21: 348-358
• 45 Blankestijn PJ, Vernooij RWM, Hockham C. et al. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. NEJM 2023; 389: 700-709
• 46 Nongnuch A, Ngampongpan W, Srichatrapimuk S. et al. Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. hemodiafiltration. PLoS One 2020; 15: e0227719
• 47 Epstein RL, Pramanick T, Baptiste D. et al. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers. J Am Soc Nephrol 2023; 34: 205-219
• 48 Sawinski D, Forde KA, Lo Re V. et al. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. Am J Kidney Dis 2019; 73: 815-826
• 49 Sarrazin C, Zimmermann T, Berg T. et al. S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion. Z Gastroenterol 2018; 56: 756-838